10 Oversold NYSE Stocks to Buy Now

5. Novo Nordisk A/S (NYSE:NVO)

YTD Decline: -45.11%

Analyst Upside: 63.48%

Number of Hedge Fund Holders: 60

Novo Nordisk A/S (NYSE:NVO) is one of the top oversold NYSE stocks to buy now. In a report released on August 4, Emily Field from Barclays maintained a Hold rating on Novo Nordisk A/S (NYSE:NVO), with a price target of DKK375.00.

In other news, Novo Nordisk A/S (NYSE:NVO) announced on August 5 the filing of 14 new lawsuits against vendors selling cheaper compounded versions of its medication semaglutide, which is marketed as the blockbuster Wegovy for obesity.

The announcement came one day after the digital weight-loss company Noom’s launch of low-dose copies of semaglutide at a considerable discount to the branded product in a market that the telehealth company Hims & Hers Health dominates.

Novo Nordisk A/S’s (NYSE:NVO) U.S. head of operations, Dave Moore, stated that:

“No one should have to gamble with their health by using knockoff drugs made with ingredients that lack oversight and safety standards. We urge regulators to enforce laws designed to protect public health.”

Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products.

Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products.